Phase II study of cyclophosphamide and hexamethylmelamine in non-oat cell bronchogenic carcinoma. 1981

M B Pisoni, and A Libretti, and E Piazza, and G Vago, and R Scapaticci, and C Bianchi, and M Tomirotti, and A Scanni, and M P Calzavara, and L Cassani, and G Scarpazza, and S Marsoni, and L Morasca

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002283 Carcinoma, Bronchogenic Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA. Carcinoma, Bronchial,Bronchial Carcinoma,Bronchial Carcinomas,Bronchogenic Carcinoma,Bronchogenic Carcinomas,Carcinomas, Bronchial,Carcinomas, Bronchogenic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006585 Altretamine A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine. Hemel,Hexamethylmelamine,Hexalen,Hexastat,Hexinawas

Related Publications

M B Pisoni, and A Libretti, and E Piazza, and G Vago, and R Scapaticci, and C Bianchi, and M Tomirotti, and A Scanni, and M P Calzavara, and L Cassani, and G Scarpazza, and S Marsoni, and L Morasca
January 1982, Cancer chemotherapy and pharmacology,
M B Pisoni, and A Libretti, and E Piazza, and G Vago, and R Scapaticci, and C Bianchi, and M Tomirotti, and A Scanni, and M P Calzavara, and L Cassani, and G Scarpazza, and S Marsoni, and L Morasca
December 1986, Cancer treatment reports,
M B Pisoni, and A Libretti, and E Piazza, and G Vago, and R Scapaticci, and C Bianchi, and M Tomirotti, and A Scanni, and M P Calzavara, and L Cassani, and G Scarpazza, and S Marsoni, and L Morasca
October 1978, Cancer treatment reports,
M B Pisoni, and A Libretti, and E Piazza, and G Vago, and R Scapaticci, and C Bianchi, and M Tomirotti, and A Scanni, and M P Calzavara, and L Cassani, and G Scarpazza, and S Marsoni, and L Morasca
December 1984, American journal of clinical oncology,
M B Pisoni, and A Libretti, and E Piazza, and G Vago, and R Scapaticci, and C Bianchi, and M Tomirotti, and A Scanni, and M P Calzavara, and L Cassani, and G Scarpazza, and S Marsoni, and L Morasca
December 1978, JAMA,
M B Pisoni, and A Libretti, and E Piazza, and G Vago, and R Scapaticci, and C Bianchi, and M Tomirotti, and A Scanni, and M P Calzavara, and L Cassani, and G Scarpazza, and S Marsoni, and L Morasca
January 1982, Cancer treatment reports,
M B Pisoni, and A Libretti, and E Piazza, and G Vago, and R Scapaticci, and C Bianchi, and M Tomirotti, and A Scanni, and M P Calzavara, and L Cassani, and G Scarpazza, and S Marsoni, and L Morasca
September 1977, Cancer treatment reviews,
M B Pisoni, and A Libretti, and E Piazza, and G Vago, and R Scapaticci, and C Bianchi, and M Tomirotti, and A Scanni, and M P Calzavara, and L Cassani, and G Scarpazza, and S Marsoni, and L Morasca
September 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M B Pisoni, and A Libretti, and E Piazza, and G Vago, and R Scapaticci, and C Bianchi, and M Tomirotti, and A Scanni, and M P Calzavara, and L Cassani, and G Scarpazza, and S Marsoni, and L Morasca
January 1982, Cancer treatment reports,
M B Pisoni, and A Libretti, and E Piazza, and G Vago, and R Scapaticci, and C Bianchi, and M Tomirotti, and A Scanni, and M P Calzavara, and L Cassani, and G Scarpazza, and S Marsoni, and L Morasca
February 1972, New York state journal of medicine,
Copied contents to your clipboard!